Deutsche Bank analyst Pito Chickering raised the firm’s price target on Zimmer Biomet to $147 from $121 and keeps a Hold rating on the shares following the Q1 beat.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ZBH:
- Zimmer Biomet price target raised to $153 from $137 at Truist
- BofA upgrades Zimmer Biomet to Neutral, says ‘no more fighting’ earnings upside
- Zimmer Biomet upgraded to Neutral from Underperform at BofA
- Zimmer Biomet price target raised to $150 from $130 at Canaccord
- Zimmer Biomet price target raised to $156 from $141 at RBC Capital